Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis
出版年份 2014 全文链接
标题
Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis
作者
关键词
Baclofen, Numerical Rating Scale, Tizanidine, Cannabidiol, Numerical Rating Scale Score
出版物
DRUGS
Volume 74, Issue 5, Pages 563-578
出版商
Springer Nature
发表日期
2014-03-26
DOI
10.1007/s40265-014-0197-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain
- (2013) Antonio García-Merino Expert Review of Neurotherapeutics
- Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines
- (2013) Ralf Gold et al. Expert Review of Neurotherapeutics
- A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers
- (2013) Colin Stott et al. SpringerPlus
- A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray
- (2012) C. G. Stott et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray
- (2012) C. G. Stott et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis
- (2012) Michael G. Serpell et al. JOURNAL OF NEUROLOGY
- Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis
- (2012) Lanting Lu et al. PHARMACOECONOMICS
- Sativex® in multiple sclerosis spasticity: a cost–effectiveness model
- (2012) John Slof et al. Expert Review of Pharmacoeconomics & Outcomes Research
- The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis
- (2012) David Baker et al. Multiple Sclerosis and Related Disorders
- Subjective and Physiological Effects After Controlled Sativex and Oral THC Administration
- (2011) E L Karschner et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Role of Cannabinoids in Multiple Sclerosis
- (2011) John P. Zajicek et al. CNS DRUGS
- A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
- (2011) A. Novotna et al. EUROPEAN JOURNAL OF NEUROLOGY
- A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)
- (2011) W Notcutt et al. Multiple Sclerosis Journal
- Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis
- (2010) Derick T Wade et al. Multiple Sclerosis Journal
- A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
- (2010) C. Collin et al. NEUROLOGICAL RESEARCH
- Validity, reliability, and clinical importance of change in a 0—10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial
- (2008) John T. Farrar et al. CLINICAL THERAPEUTICS
- Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors
- (2007) G Pryce et al. BRITISH JOURNAL OF PHARMACOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now